Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Acorda Therapeutics announces initiation of AMPYRA® proof-of-concept study in patients with post-stroke deficits
Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomised, double-blind, placebo-controlled proof-of-concept clinical trial.
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.
Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.
Oligodendrocyte death results in immune-mediated CNS demyelination.
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
European Commission Approves Genzyme’s Once-Daily, Oral Multiple Sclerosis Treatment Aubagio® (teriflunomide)
Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth.
Dose comparison trial of sustained-release fampridine in multiple sclerosis.
Imovane: Best Online Pharmacy
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
Fourth PML Case With Tecfidera in MS Calls for Vigilance
TECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness
Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics.
Molecular mechanism underlying the impact of vitamin D on disease activity of MS.
Fatal Acute Myeloid Leukemia With 11q23 MLL Gene Rearrangement Following Mitoxantrone Treatment in a Case of Childhood-onset Multiple Sclerosis.
What Explains Gray Matter Atrophy in Long-standing Multiple Sclerosis?
Novel therapies for memory cells in autoimmune diseases.
Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study.
Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy.
Multiple sclerosis: risk factors, prodromes, and potential causal pathways.
Oxidative modification of serum proteins in multiple sclerosis.
US court permits generic version of Teva MS drug a year sooner
The interplay between the intestinal microbiota and the brain.

Pages